Optimising In Vivo Tumour Models for Translational Success: Exploring Strategies to Overcome Preclinical Oncology Modelling Limitations

• Evaluating in vivo systems for small molecules and immuno-oncology agents, and identifying factors that influence predictive accuracy
• Addressing common pitfalls such as overinterpretation and variability in terminated studies to refine efficacy assessment
• Implementing strategies to improve data relevance, including better understanding of tumour microenvironment and immune interactions

Speakers:

Anil Thotakura

Head of Immuno-Oncology

Orion Pharma